In acute myeloid leukemia (AML), overexpression of CPT1A indicates poor clinical prognosis, and strong synergistic inhibitory effects on AML were seen when the CPT1A-selective inhibitor ST1326 and the Bcl-2 inhibitor ABT199 were applied in combination (Mao et al., 2021). This evidence concerns the gene BCL2 and acute myeloid leukemia.